Seroprevalence of human T-lymphotropic virus type I or II in sexually transmitted disease clinic patients in the USA.
Serum specimens from patients attending sexually transmitted disease (STD) clinics in Denver and several southeastern US cities were tested for antibody to human T-lymphotropic virus type I or II (HTLV-I/II). In Denver, 8 (2.1%) of 384 patients with a history of intravenous (IV) drug use, versus none of 201 non-IV-drug users, were HTLV-I/II seropositive. Only 2 (0.18%) of 1095 STD clinic patients from the southeastern USA had antibodies to HTLV-I/II. These data document a low prevalence of HTLV-I/II in STD clinic patients from the southeastern USA and confirm that IV drug use is an important risk factor for HTLV-I/II in the USA.
Khabbaz
R F
RF
Division of Viral Diseases, Centers for Disease Control, Atlanta, GA 30333.
Douglas
J M
JM
Judson
F N
FN
Spiegel
R A
RA
St Louis
M E
ME
Whittington
W
W
Hartley
T M
TM
Lairmore
M
M
Kaplan
J E
JE
D000328:Adult; D001741:Black or African American; D015153:Blotting, Western; D003120:Colorado; D005260:Female; D006679:HIV Seropositivity / Q000150:complications; D015481:HTLV-I Antibodies / Q000032:analysis*; D015490:HTLV-I Infections / Q000150:complications / Q000453:epidemiology*; D015482:HTLV-II Antibodies / Q000032:analysis*; D015491:HTLV-II Infections / Q000150:complications / Q000453:epidemiology*; D006630:Hispanic or Latino; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D015995:Prevalence; D015531:Radioimmunoprecipitation Assay; D012307:Risk Factors; D012737:Sex Factors; D012749:Sexually Transmitted Diseases / Q000150:complications*; D015144:Southeastern United States; D015819:Substance Abuse, Intravenous / Q000150:complications; D044465:White People
D015481:HTLV-I Antibodies; D015482:HTLV-II Antibodies